Comprehensive Updates in the Role of Imaging for Multiple Myeloma Management Based on Recent International Guidelines
暂无分享,去创建一个
Jeong Hyun Lee | E. Chae | H. Chung | J. Ryu | Y. Ko | K. Kim | Ho Young Park | Koeun Lee
[1] Jeong Hyun Lee,et al. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response , 2020, Cancer Imaging.
[2] H. Goldschmidt,et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. , 2019, The Lancet. Oncology.
[3] M. Mohty,et al. Current status of autologous stem cell transplantation for multiple myeloma , 2019, Blood Cancer Journal.
[4] Kyu-Won Jung,et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.
[5] V. Goh,et al. Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. , 2018, Critical reviews in oncology/hematology.
[6] R. Greil,et al. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe , 2018, Expert review of hematology.
[7] Nickolas Papanikolaou,et al. Functional and molecular MRI of the bone marrow in multiple myeloma. , 2018, The British journal of radiology.
[8] T. Spektor,et al. Monitoring multiple myeloma. , 2017, Clinical advances in hematology & oncology : H&O.
[9] F. Gherlinzoni,et al. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. , 2017, Clinical radiology.
[10] H. Goldschmidt,et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group , 2017, Blood Cancer Journal.
[11] Vicky Goh,et al. Guidelines for the use of imaging in the management of patients with myeloma , 2017, British journal of haematology.
[12] J. Oldan,et al. PET/MR Imaging of Multiple Myeloma. , 2017, Magnetic resonance imaging clinics of North America.
[13] Bart Barlogie,et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.
[14] S. Raza,et al. The Critical Role of Imaging in the Management of Multiple Myeloma , 2017, Current Hematologic Malignancy Reports.
[15] C. Hofmeister,et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] M. Dimopoulos,et al. Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. , 2017, Radiology.
[17] H. Goldschmidt,et al. Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group , 2016 .
[18] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[19] T. Plesner,et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference , 2016, Clinical chemistry and laboratory medicine.
[20] K. Verstraete,et al. Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma. , 2016, European journal of radiology.
[21] F. Cretti,et al. Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM) , 2016, La radiologia medica.
[22] S. Ailawadhi. The Changing Face of Multiple Myeloma , 2015 .
[23] Jian Hou,et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] K. Verstraete,et al. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma , 2014, European Radiology.
[25] G. Morgan,et al. The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma , 2014, Expert review of hematology.
[26] R. Eslick,et al. Multiple myeloma: from diagnosis to treatment. , 2013, Australian family physician.
[27] K. Verstraete,et al. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. , 2013, European journal of radiology.
[28] G. Morgan,et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. , 2012, The British journal of radiology.
[29] M. Dimopoulos,et al. Advances in imaging and the management of myeloma bone disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] H. Goldschmidt,et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Tobias Bäuerle,et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] B. Pégourié,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.
[33] B. Barlogie,et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Reiser,et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.
[35] M. Dimopoulos,et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. , 1992, Radiology.
[36] R. Kyle,et al. Smoldering multiple myeloma. , 1980, The New England journal of medicine.
[37] N. Pandit-Taskar. Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. , 2018, Seminars in hematology.
[38] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[39] M. Dimopoulos,et al. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[40] Jun Zhang,et al. A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease--which is best? , 2014, Asian Pacific journal of cancer prevention : APJCP.
[41] M. Dreyling,et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] P. Greipp,et al. Biology and treatment of myeloma. , 1996, Current opinion in oncology.
[43] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[44] G. Edelstyn,et al. The radiological demonstration of osseous metastases. Experimental observations. , 1967, Clinical radiology.
[45] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.